The Prognostic Significance Of Inflammation Associated Blood Cell Markers In Metastatic Colorectal Cancer

Öz

Objectives: The aim is to perform prognostic evaluation with overall survival (OS) and progression-free survival (PFS) in hematological parameter-based groups in patients with metastatic colorectal cancer (mCRC). Methods: In a single institution, 51 patients were retrospectively analyzed mCRC diagnosed between 2019 and 2022. Pretreatment hematological parameters of patients with mCRC receiving first-line chemotherapy in a single center were examined. The receiver operating characteristic curve was used to predict the tests. Median OS was calculated by the Kaplan-Meier method and compared with the log-rank test. Multivariate analyses were performed using a Cox regression model. Results: The median OS of the patients included in the study was 27 months (3-88 months) by statistical calculation; the median PFS was 19 months (2-84 months). The median could not be reached. Among the risk factors affecting OS, it was found effective to have a bone metastasis site and a pancreatic metastasis site (p values 0.003 and 0.027, respectively). In the analysis of the risk factors affecting PFS, bone and pancreatic metastases were found to be significant (p values 0.001 and 0.004, respectively). Patients receiving chemotherapy and anti-VEGF therapy have a significantly reduced risk of death of 0.06 times compared to those who do not receive chemotherapy, which indicates that OS is significantly longer in people receiving chemotherapy in question (p=0.020). It was observed that blood cell marker levels were not statistically significant in PFS and OS. Of the 51 patients included in the study, 30 of them were still being followed up, while 21 of them died. Conclusions: Chemotherapy plus anti-VEGF therapy is a treatment whose effectiveness has been determined in metastatic colorectal cancer. In the future, there is a need for more prospective and large patient group studies on this topic to measure the prognostic value of hematological parameters in metastatic colorectal cancer.

Anahtar Kelimeler

• Colorectal cancer
• Progression free survival
• Overall survival

Kaynakça

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. doi:10.1016/j.cell.2010.01.025
2. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. Published 2014 May 29. doi:10.1093/jnci/dju124
3. Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017;12(5):e0177137. Published 2017 May 10. doi:10.1371/journal.pone.0177137
4. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24(4):381-396. doi:10.1016/j.bpg.2010.06.004
5. Pedrazzani C, Mantovani G, Fernandes E, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017;7(1):1494. Published 2017 May 4. doi:10.1038/s41598-017-01652-0
6. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-2418. doi:10.1158/1055-9965.EPI-05-0316
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
8. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403-2413. doi:10.1002/ijc.28536

9. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86-105. doi:10.3109/10408363.2014.992064
10. Hu Z, Sun Y, Wang Q, et al. Red blood cell distribution width is a potential prognostic index for liver disease. Clin Chem Lab Med. 2013;51(7):1403-1408. doi:10.1515/cclm-2012-0704
11. Li N, Zhou H, Tang Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Dis Markers. 2017;2017:7089493. doi:10.1155/2017/7089493
12. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med. 2009;169(5):515-523. doi:10.1001/archinternmed.2009.11
13. Hu L, Li M, Ding Y, et al. Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(9):16027-16035. doi:10.18632/oncotarget.13784
14. Koma Y, Onishi A, Matsuoka H, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013;8(11):e80240. Published 2013 Nov 11. doi:10.1371/journal.pone.0080240
15. Zhao T, Cui L, Li A. The significance of RDW in patients with hepatocellular carcinoma after radical resection. Cancer Biomark. 2016;16(4):507-512. doi:10.3233/CBM-160591
16. Yazici P, Demir U, Bozkurt E, Isil GR, Mihmanli M. The role of red cell distribution width in the prognosis of patients with gastric cancer. Cancer Biomark. 2017;18(1):19-25. doi:10.3233/CBM-160668
17. Chen GP, Huang Y, Yang X, Feng JF. A Nomogram to Predict Prognostic Value of Red Cell Distribution Width in Patients with Esophageal Cancer. Mediators Inflamm. 2015;2015:854670. doi:10.1155/2015/854670
18. Huang DP, Ma RM, Xiang YQ. Utility of Red Cell Distribution Width as a Prognostic Factor in Young Breast Cancer Patients. Medicine (Baltimore). 2016;95(17):e3430. doi:10.1097/MD.0000000000003430
19. Janakiram NB, Rao CV. The role of inflammation in colon cancer. Adv Exp Med Biol. 2014;816:25-52. doi:10.1007/978-3-0348-0837-8_2
20. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114.e5. doi:10.1053/j.gastro.2010.01.058
21. Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119(1):40-51. doi:10.1038/s41416-018-0095-9
22. Wang F, He W, Jiang C, et al. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer. BMC Cancer. 2018;18(1):1102. Published 2018 Nov 12. doi:10.1186/s12885-018-4842-3
23. Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113(2):204-211. doi:10.1038/bjc.2015.87
24. Argiles G, Yoshino T, Ohtsu A, et al. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. [abstract 744]. J Clin Oncol 2018;36: [Available online at: https://ascopubs.org/doi/10.1200/ JCO.2018.36.4_suppl.744; cited 26 August 2020]
25. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16(3):614-622. doi:10.1245/s10434-008-0267-6
26. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44-70. doi:10.1093/annonc/mdx738
27. Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014;20(4):899-907. doi:10.3748/wjg.v20.i4.899
28. De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol. 2014;20(41):15049-15059. doi:10.3748/wjg.v20.i41.15049
29. Faria SS, Fernandes PC Jr, Silva MJ, et al. The neutrophil-to- lymphocyte ratio: a narrative review. EcancerMedical Science 2016;10:702.
30. Ma JP, Wang Z, Lin JW et al. Neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2011;14:944-947.
31. Teramukai S, Kitano T, Kishida Y et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009;45:1950-1958.
32. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan C, Clarke SJ. The systemic inflammation-based neutrophil lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-230.
33. Qian BZ. Inflammation fires up cancer metastasis. Semin Cancer Biol 2017;47:170-6.
34. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
35. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359-369. doi:10.6004/jnccn.2018.0021
36. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288-1295.
37. Qian W, Ge XX, Wu J, et al. Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators. Oncol Lett. 2019,18(1):571-80.
38. Wu YY, Zhang X, Qin YY, et al. Mean platelet volume/platelet count ratio in colorectal cancer: a retrospective clinical study. BMC Cancer. 2019,19(1):314.
39. Takeuchi H, Abe M, Takumi Y, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer. PLoS One. 2017,12(12):e0189166.
40. Vayrynen JP, Vayrynen SA, Sirnio P, et al. Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. J Transl Med. 2019,17(1):199.
41. Lin MS, Huang JX, Zhu J, et al. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 2012,59(118):1687-90.
42. Peng HX, Lin K, He BS, et al. Platelet-to-lymphocyte ratio could be a promising prognostic biomarker for survival of colorectal cancer: a systematic review and meta-analysis. FEBS Open Bio. 2016,6(7):742-50.
43. Azab B, Mohammad F, Shah N, et al. The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer. Cancer Biomark. 2014,14(5):303-12.
44. Huang Y, Cui MM, Huang YX, et al. Preoperative platelet distribution width predicts breast cancer survival. Cancer Biomark. 2018,23(2):205-11.
45. Cui MM, Li N, Liu X, et al. Platelet distribution width correlates with prognosis of non-small cell lung cancer. Sci Rep. 2017,7(1):3456.
46. Zhang X, Cui MM, Fu S, et al. Platelet distribution width correlates with prognosis of gastric cancer. Oncotarget. 2017,8(12):20213-9.
47. Duraker, N, Çaynak ZC, Hot S. The impact of primary tumor resection on overall survival in patients with colorectal carcinoma and unresectable distant metastases: A prospective cohort study. IJS 2014, 12(7): 737-41.
48. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678-700. doi:10.1200/JCO.22.01690
49. Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;118:54-62. doi:10.1016/j.critrevonc.2017.08.006
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. doi:10.1056/NEJMoa032691
51. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [published correction appears in N Engl J Med. 2010 Dec 23;363(26):2573]. N Engl J Med. 2009;360(6):563-572. doi:10.1056/NEJMoa0808268